Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity Read More February 10, 2025 Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results Read More February 10, 2025 Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with...
加利福尼亚州帕萨迪纳 - 市值21.9亿美元的Arrowhead Pharmaceuticals, Inc.(纳斯达克股票代码:A... 提供者Investing.com •2025年3月06日 Arrowhead制药CEO出售价值527万美元股票 加利福尼亚州帕萨迪纳讯—Arrowhead制药公司(NASDAQ:ARWR)首席执行官Christopher Anza... ...
近日,Arrowhead Pharmaceuticals(以下简称“Arrowhead”)在肥胖/代谢研发网络研讨会上宣布,将推进两款新一代RNAi候选药物——ARO-INHBE和ARO-ALK7进入临床试验阶段,用于治疗肥胖症和代谢性疾病。Arrowhead计划在2024年底前向监管机构提交IND申请,...
Arrowhead Pharmaceuticals GAAP EPS of -$1.39 misses by $1.01, revenue of $2.5M misses by $16.55MSA NewsMon, Feb. 10 Arrowhead Pharmaceuticals, Inc. SEC Filing - Quarterly Report (10-Q) February 10, 2025SEC FilingsMon, Feb. 10 Arrowhead Pharmaceuticals Q1 2025 Earnings PreviewSA NewsSun, ...
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfoli...
医麦客新闻 eMedClub News 近日,Arrowhead Pharmaceuticals(以下简称“Arrowhead”)在肥胖/代谢研发网络研讨会上宣布,将推进两款新一代RNAi候选药物——ARO-INHBE和ARO-ALK7进入临床试验阶段,用于治疗肥胖症和代谢性疾病。Arrowhead计划在2024年底前向监管机构提交IND申请,并于2025年初启动针对肥胖受试者的临床研究。
LatestArrowhead PharmaceuticalsNews Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages May 16, 2025 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Posted by MarketBeat News...
Last Updated on October 25, 2024 Arrowhead Pharmaceuticals, Inc. (“Arrowhead”, “we”, “us”, or “our”) is committed to protecting your privacy. This Privacy Policy describes our practices regarding the collection, use, and disclosure of your Personal Information (as defined below) when ...
Arrowhead与Sarepta完成5亿美元授权协议ARWR -6.02% 加利福尼亚州帕萨迪纳 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) 目前交易价格为$20.24,过去一周上涨8%。在Hart-Scott-Rodino反托拉斯改进法案规定的等待期届满后,该公司已与Sarepta Therapeutics (NASDAQ: SRPT)完成了授权和合作协议。根据InvestingPro分析...
Arrowhead Pharmaceuticals, Inc. today announced topline results from Part 2 of a Phase 1/ 2 clinical study of ARO-C3, the company’ s investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potentia